

ADULT Treatment Guidance for COVID-19 in the Ambulatory Setting

Updated 2/15/2021

Available Therapy through Emergency Use Authorization (EUA)

(Subject to change as more data becomes available and based on medication availability)

Drug	Mechanism	Rationale for use	Recommendation
Bamlanivimab	Inhibits viral attachment to human ACE2 receptor	Neutralizing monoclonal antibodies that bind to the spike protein of SARS-CoV-2, preventing spike protein attachment to ACE2 receptor	<ul style="list-style-type: none"> ▪ EUA granted for the treatment of non-hospitalized patients with mild-moderate COVID-19 who are at high risk for disease progression. ▪ Bamlanivimab reduced the need for hospitalization compared with placebo in the BLAZE-1 trial.¹ ▪ Casirivimab/imdevimab reduced the rates of medically attended visits (MAVs) in an ongoing randomized trial² ▪ <u>Current YNHH criteria for approval:</u> <ul style="list-style-type: none"> ▪ Patients must be 12 years of age and older, weigh at least 40 kg, have a documented positive result of a direct SARS CoV-2 viral test within the last 7 days AND meet the following criteria listed below: <ul style="list-style-type: none"> ▪ Patients ≥ 65 years of age ▪ Patient less than 65 years of age AND have one of the following co-morbidities: <ul style="list-style-type: none"> • Diabetes mellitus • BMI > 40 kg/m² • Chronic Kidney Disease, Stage III or higher or receiving dialysis • Congestive Heart Failure NYHA Class III or higher • Severe pulmonary disease defined as one of the following: <ul style="list-style-type: none"> ○ COPD with continuous home oxygen, pulmonary hypertension/pulmonary fibrosis, or cystic fibrosis • Cirrhosis—Child Class B or C • Immunosuppressed status due to an underlying immunocompromising condition or use of immunosuppressive therapy • Sickle cell disease • Parkinson’s disease ▪ Patient aged 12-17 with one of the following: <ul style="list-style-type: none"> • Congenital or acquired heart disease • Neurodevelopmental disorders • Medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19) • Chronic respiratory disease excluding asthma
Casirivimab/ imdevimab			

			<ul style="list-style-type: none"> ▪ <u>Current YNHH exclusion criteria:</u> <ul style="list-style-type: none"> ▪ Hospitalized due to COVID-19 <ul style="list-style-type: none"> ▪ Monoclonal antibodies, such as bamlanivimab or casirivimab/imdesivimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation. ▪ OR ▪ Patients who require oxygen therapy due to COVID-19 or who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity. <ul style="list-style-type: none"> ▪ Pregnancy and/or lactation is not a contraindication for use, however, recommended risks versus benefits are discussed with patient’s OB/GYN and/or pediatrician. <ul style="list-style-type: none"> ▪ For more information on how to refer patients for monoclonal antibody therapy, refer to Epic tools under “COVID-19 Monoclonal Antibody References” or copy and paste the following link into your browser: https://www.ynhhs.org/patient-care/covid-19/for-employees/for-employees.aspx <ul style="list-style-type: none"> ▪ Scroll to <i>Outpatient Clinical Resources</i> and find <i>COVID-19 Monoclonal Antibody Therapy Tips and Tricks for Referrals</i>
--	--	--	---

Available Therapy through Clinical Trial
Referral for Outpatient Clinical Trials: 1-877-978-8343
(Subject to change as more data becomes available and based on medication availability)

Camostat mesilate	Protease inhibitor	Inhibits human transmembrane surface protease, TMPRSS2, responsible for priming the SARS-CoV-2 spike protein ³	<ul style="list-style-type: none"> ▪ Currently under investigation for potential treatment of COVID-19 infection ▪ Has been shown <i>in vitro</i> and in animal models to inhibit SARS-CoV-2 viral replication at clinically achievable blood and respiratory tract concentration⁴ ▪ Currently enrolling ambulatory patients for phase II randomized, double-blind, placebo controlled trial ▪ Eligibility criteria: <ul style="list-style-type: none"> ▪ Adults 18 years of age and older ▪ Positive SARS CoV-2 viral test within the last 3 days ▪ Experiencing mild symptoms (fever/ temperature > 100.4, loss of taste or smell, cough, sore throat, or gastrointestinal complaints such as nausea, vomiting or diarrhea, chills, congestion or runny nose, headaches, muscle or body aches, fatigue) ▪ OR ▪ No symptoms but recent exposure to an individual with a confirmed COVID-19 diagnosis <ul style="list-style-type: none"> ▪ Patient Referrals:
-------------------	--------------------	---	---

			<ul style="list-style-type: none"> ▪ 1-877-978-8343 ▪ Principle investigator(s)/ Contact information: <ul style="list-style-type: none"> ▪ PI: Geoffrey Chupp, MD (geoffrey.chupp@yale.edu) ▪ Lead CRC: Angela Ryan Nuñez (angela.nunez@yale.edu) (203) 393-6591
Apilimod	IL-12/IL-23 inhibitor	Inhibits PIKfyve, an enzyme involved in the endocytosis and fusion of SARS-CoV-2 ⁵	<ul style="list-style-type: none"> ▪ Currently under investigation for potential treatment of COVID-19 infection ▪ <i>In vitro</i> data demonstrates potent inhibition of SARS-CoV-2 infection⁵ ▪ Currently enrolling patients for phase II randomized, double-blind, placebo controlled trial ▪ Eligibility criteria: <ul style="list-style-type: none"> ▪ Adults 18 years of age and older ▪ SARS CoV-2 positive by validated test ▪ Mild symptoms characterized by >= 1 of the following: presence of fever (temperature ≥100.4), anosmia (loss of taste or smell), cough, sore throat, or gastrointestinal complaints (e.g. nausea, vomiting, or diarrhea), chills, congestion or runny nose, headaches, muscle or body aches, fatigue, without shortness of breath or dyspnea (RR<20, SpO2 >93% on room air), OR <ul style="list-style-type: none"> ▪ Asymptomatic patients who have tested positive for COVID-19 within the past 4 days. ▪ Patient Referrals: <ul style="list-style-type: none"> ▪ 1-877-978-8343 ▪ Principle investigator(s)/Contact Information: <ul style="list-style-type: none"> ▪ PI: Charles Dela Cruz, MD, PhD (Charles.delacruz@yale.edu) ▪ Lead CRC: Lindsey Frackiewicz (Lindsey.frackiewicz@yale.edu) (203) 747-1845
Medications <u>NOT</u> Recommended for Outpatient Use			
(Only recommended for the treatment of COVID-19 in HOSPITALIZED patients)			
Dexamethasone	Immune system modulation	Inhibit production of inflammatory cytokines that regulate neutrophil and T-cell responses	<ul style="list-style-type: none"> ▪ There is insufficient evidence to support the use of dexamethasone for OUTPATIENTS with COVID-19 ▪ The RECOVERY trial compared the use of oral or IV dexamethasone (6mg once daily) for up to ten days vs. standard of care in hospitalized patients with COVID-19⁶ ▪ Results demonstrated a benefit with dexamethasone among patients requiring any oxygen supplementation ▪ There are no studies to date, however, that demonstrate benefit in non-hospitalized patients
Anticoagulation	Anti-coagulants	Prevent thrombotic events associated with SARS-CoV-2 infection	<ul style="list-style-type: none"> ▪ There is insufficient evidence to support the use of anticoagulation for OUTPATIENTS with COVID-19 ▪ Please see Appendix 1 for more information on the use of anti-coagulants in patients discharged from the hospital following admission for COVID-19

Medications with NO Proven Clinical Efficacy for the PREVENTION of COVID-19

<p style="text-align: center;">Vitamin D2 (ergocalciferol)</p> <p style="text-align: center;">&</p> <p style="text-align: center;">Vitamin D3 (cholecalciferol)</p>	<p style="text-align: center;">Immune system modulation⁷</p>	<p style="text-align: center;">Lower viral replication⁸</p> <p style="text-align: center;">Reduce mortality⁸</p> <p style="text-align: center;">Vitamin D deficiency linked with cytokine storm biomarkers⁹⁻¹¹</p>	<ul style="list-style-type: none"> ▪ There is insufficient evidence to recommend vitamin D for prevention of COVID-19 ▪ Patients who require vitamin D replacement can continue or be initiated as appropriate ▪ There are no completed trials to date evaluating the use of Vitamin D for COVID-19. There are ongoing clinical trials assessing potential benefit.^{12,13} ▪ There is conflicting evidence regarding the benefits of Vitamin D in preventing other respiratory viral infections, such as influenza. In these studies, several studies using lower doses of Vitamin D support its benefit in preventing respiratory tract infections¹³⁻¹⁵, while another showed opposite effects in pediatric patients¹⁶, and other studies showed mixed results.¹⁷
<p style="text-align: center;">Zinc</p>	<p style="text-align: center;">Supplement</p>	<p style="text-align: center;">Increased intracellular concentrations of zinc impair replication in a number of RNA viruses like SARS- CoV-2¹⁸</p>	<ul style="list-style-type: none"> ▪ There is no data to support the use of zinc for the prevention of COVID-19 ▪ The NIH COVID-19 Treatment Guidelines recommend against using zinc supplementation above the recommended dietary allowance for the prevention of COVID-19 (11 mg daily for men and 8 mg for non-pregnant women) ▪ Retrospective data investigating the benefits of zinc supplementation was flawed as patients who received zinc had higher baseline absolute lymphocyte counts compared with those who did not receive zinc¹⁹
<p style="text-align: center;">Vitamin C</p>	<p style="text-align: center;">Anti-oxidant</p>	<p style="text-align: center;">Decrease inflammation and vascular injury in patients with COVID-19</p>	<ul style="list-style-type: none"> ▪ There is insufficient data to recommend the use of vitamin C for the prevention of COVID-19 ▪ Patients who are not critically ill are less likely to experience oxidative stress or severe inflammation, so the role of vitamin C in this setting is unknown ▪ There are no completed clinical trials of vitamin C in patients with COVID-19, and the available observational data are sparse and inconclusive
<p style="text-align: center;">Famotidine & Cetirizine</p>	<p style="text-align: center;">Anti- histamines</p>	<p style="text-align: center;">Potential inhibition of 3CL protease and of histamine- mediated cytokine storm</p>	<ul style="list-style-type: none"> ▪ There is insufficient evidence to support the use of famotidine or combination histamine blockers to prevent COVID-19 ▪ A retrospective cohort study comparing 84 patients treated with famotidine against 1536 patients not receiving famotidine concluded that famotidine may decrease the composite outcome of death or intubation (HR 0.42; 0.21 to 0.85), however the IDSA guidelines determined this to be very low level evidence given high suspicion of publication bias²⁰ ▪ A physician-sponsored cohort study in hospitalized patients found a reduction in the progression of symptoms with the combination of famotidine and cetirizine. However, this study is limited by study design and the number of patients not receiving dual antihistamine therapy (12 compared to 110)²¹ ▪ No published randomized controlled trial supports the use of famotidine for the prevention or treatment of COVID-19
<p style="text-align: center;">HMG-CoA reductase inhibitors (statins)</p>	<p style="text-align: center;">HMG-CoA reductase inhibition</p>	<p style="text-align: center;">Inhibition of MYD88 pathway related to immunity²²⁻²⁴</p>	<ul style="list-style-type: none"> ▪ There is insufficient evidence to recommend statins for the prevention of COVID-19 ▪ Patients who require statins for non-COVID indications should be continued or initiated

		Lower incidence of viral pneumonia ²⁵⁻²⁷	<ul style="list-style-type: none"> No published peer review studies in medical literature were found to support the usage of statins based solely on COVID positive status. Further studies are necessary to connect its relationship with COVID-19. Current NIH COVID-19 guidance does not recommend to use statins to treat COVID.
Medications with NO Proven Clinical Efficacy for the TREATMENT of COVID-19			
Hydroxychloroquine	Prevents acidification of endosomes interrupting cellular functions and replication	Early <i>in-vitro</i> data showed potent SARS-COV-2 inhibition and early clinical data showed possible benefit	<ul style="list-style-type: none"> Available data from clinical trials does not demonstrate benefit, and some studies suggest risk. Risks outweigh benefits given theoretic risk for cardiac arrhythmia. Among patients hospitalized with Covid-19, those who received hydroxychloroquine did not have a lower incidence of death at 28 days than those who received usual care.^{28,29}
Azithromycin and other antibiotics	Possible immuno-modulator	In a small study, combination of HCQ and azithromycin was associated with significant a reduction in SARS-CoV-2 viral load	<ul style="list-style-type: none"> There is a lack of clinical data to support the use of azithromycin for the treatment of COVID-19 There is very limited data on use of azithromycin alone or in combination with other agents Gautret, et al. study is limited by small sample size (only 6 patients received HCQ & azithromycin combination) and those patients had lower viral loads than other included patients³⁰ Combination of HCQ and azithromycin and atazanavir can increase the risk for QTc prolongation Of note, antibiotics in general are not recommended for the treatment of COVID-19
Ivermectin	Inhibition of SARS CoV-2 viral replication	In vitro data demonstrated potent inhibition of viral inhibition ³¹	<ul style="list-style-type: none"> There is a lack of clinical data to support the use of ivermectin for the treatment of COVID-19 Although <i>in-vitro</i> data demonstrated potent anti-SARS CoV-2 activity, further validation with <i>in vivo</i> models is required
Aspirin	COX- 1/2 inhibition	Prevent thromboembolic events associated with COVID-19	<ul style="list-style-type: none"> There is insufficient evidence to support the initiation of aspirin in non-hospitalized patients with COVID-19 Patients who take aspirin should CONTINUE TREATMENT for other underlying medical conditions unless they develop significant bleeding or other contraindications³² Sufficiently powered randomized controlled trials are needed to assess the efficacy of aspirin in patients with COVID-19
Vitamin D2 (ergocalciferol)		Lower viral replication ⁸ Reduce mortality ⁸ Vitamin D	<ul style="list-style-type: none"> There is insufficient evidence to recommend vitamin D for the treatment of COVID-19 Patients who require vitamin D replacement can continue or be initiated as appropriate Some recently published retrospective observational studies concluded that patients with COVID-19 had lower levels of vitamin D.^{32,33} While these patients may need vitamin D

& Vitamin D3 (cholecalciferol)	Immune system modulation ⁷	deficiency linked with cytokine storm biomarkers ⁹⁻¹¹	replacement regardless of COVID-19 prevention, further clinical trials are necessary to connect its relationship with COVID-19.
Zinc	Supplement	Increased intracellular concentrations of zinc impair replication in a number of RNA viruses like SARS-CoV-2 ¹⁸	<ul style="list-style-type: none"> ▪ There is no data to support the use of zinc for the treatment of COVID-19 ▪ Retrospective data investigating the benefits of zinc supplementation was flawed as patients who received zinc had higher baseline absolute lymphocyte counts compared with those who did not receive zinc¹⁹
Vitamin C	Anti-oxidant	Decrease inflammation and vascular injury in patients with COVID-19	<ul style="list-style-type: none"> ▪ There is insufficient data to recommend the use of vitamin C for the treatment of COVID-19 ▪ Patients who are not critically ill are less likely to experience oxidative stress or severe inflammation, so the role of vitamin C in this setting is unknown ▪ There are no completed clinical trials of vitamin C in patients with COVID-19, and the available observational data are sparse and inconclusive
Famotidine & Cetirizine	Anti-histamines	Potential inhibition of 3CL protease and of histamine-mediated cytokine storm	<ul style="list-style-type: none"> ▪ There is insufficient evidence to support the use of famotidine or combination histamine blockers to treat COVID-19 ▪ A retrospective cohort study comparing 84 patients treated with famotidine against 1536 patients not receiving famotidine concluded that famotidine may decrease the composite outcome of death or intubation (HR 0.42; 0.21 to 0.85), however IDSA guidelines determined this to be very low level evidence given high suspicion of publication bias²⁰ ▪ No published randomized controlled trial supports the use of famotidine for the treatment of COVID-19
Medications with Insufficient Evidence for Routine Clinical Use for COVID-19			
Colchicine ³⁴	Anti-gout agent	Anti-inflammatory and anti-viral properties ³⁵ Inhibition of PMN cell migration	<ul style="list-style-type: none"> ▪ The use of colchicine for the treatment of COVID-19 is not currently recommended by national or international guidelines ▪ The COLCORONA phase III trial to evaluate the efficacy and safety of colchicine for 30 days in adult outpatients diagnosed with COVID-19 infection which showed a mild potential decrease in the composite endpoint of hospitalization and death is now in preprint; however further peer reviewed studies are needed to verify these findings. Of note, there were also a large number of patients who developed gastrointestinal adverse effects from this therapy in the trial as well. Therefore, it is unclear if this potential benefit outweighs the adverse effects from treatment.³⁴
Fluvoxamine ^{36,37}	SSRI	Potential immune modulation via σ -1	<ul style="list-style-type: none"> ▪ There is insufficient evidence to support the use of fluvoxamine for the treatment of COVID-19 and it is not currently recommended by national or international guidelines

	σ-1 receptor agonist	receptor (S1R) agonism ³⁶	<ul style="list-style-type: none"> A randomized trial found a lower likelihood of clinical deterioration in adult outpatients with COVID-19 treated with fluvoxamine compared with placebo³⁶, however this study had several limitations including small sample size and potential for bias given primary and secondary endpoints were measured using participants' self-reported responses on surveys.
Medications with Previous Safety Concerns in COVID-19			
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)	COX-1/2 inhibition	Potentially increases ACE2 expression resulting in worsened COVID-19 infection	<ul style="list-style-type: none"> Appropriate to use in COVID-19 patients Considerations for NSAID prescribing should always include evaluation of inherent NSAID side effects (i.e. risk of renal dysfunction), regardless of COVID-19 diagnosis No published peer reviewed studies support NSAIDs worsening COVID-19 infections. European Medicines Agency (EMA) and the Food and Drug Administration (FDA) issued statements that there is no scientific evidence connecting NSAID use and worsening COVID-19 symptoms^{38,39}
Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors	ACE inhibition and ARB antagonist	Potentially increases ACE2 expression resulting in worsened COVID-19 infection	<ul style="list-style-type: none"> RAAS antagonists should be continued for patients currently prescribed such agents for other underlying medical conditions such as heart failure, hypertension, or ischemic heart disease. Two recent observational studies found no association between ACEI or ARB use and COVID-19 positivity or infection-related morbidity/mortality^{40,41} Additionally, a retrospective multicenter study of 1128 patients with hypertension and COVID-19 admitted to 9 hospitals in Hubei, China found that ACEI/ARB use may have been associated with lower risk of all-cause mortality⁴²

Appendix 1: Recommendations on the management of anticoagulation in patients discharged from the hospital

1. Patients who had initiation of treatment doses during the hospital stay for either presumed or objectively documented venous thrombosis should be discharged on full dose anticoagulation therapy (Direct oral anticoagulant (DOAC), LMWH, warfarin) for a minimum treatment period of three months.
 - We recommend that these patients have follow up with their primary care physician or specialty physician within six weeks of discharge to assess ongoing risk benefit ratio of anticoagulation.

2. Patients who received standard dose VTE prophylaxis in hospital should not ordinarily continue with VTE prophylaxis. If, however, they are being discharged to another medical care facility, standards of care at that facility should prevail.

3. Patients who received escalated dose (intermediate dose) VTE prophylaxis could be considered for extended VTE prophylaxis with rivaroxaban 10 mg daily for 35 days or LMWH if rivaroxaban cannot be used. The following conditions can be used to determine if a patient is eligible to receive extended duration VTE prophylaxis:
 - Patient should have either:
 1. Modified IMPROVE VTE Risk Score is ≥ 4
 2. Modified IMPROVE VTE Risk Score is 2 or 3 and a D-dimer is $> 2x$ ULN. (D-dimer measured within 24 hours of discharge should be used for this determination)
 - Patient should **NOT** have any of the following:
 1. Major bleeding during hospital stay or during the three months prior to index hospital stay
 2. Major surgery within the last four weeks
 3. Prolonged PT (INR > 1.5 - measured within 24 hours of discharge)
 4. Known bleeding disorder
 5. Current use of anti-platelet therapy
 6. CrCl of < 30 mL/min
 7. Discharge platelet count $< 100,000/ul$ (measured within 24 hours of discharge)
 8. Other contraindications to anticoagulation with a DOAC

Calculating the Modified IMPROVE VTE Risk Score

VTE Risk Factor	VTE Risk Score
Previous VTE	3
Known thrombophilia*	2
Current lower limb paralysis or paresis**	2
History of cancer‡	2
ICU/CCU Stay	1
Complete immobilization ≥ 1 day*	1
Age ≥ 60 years	1

*A congenital or acquired condition leading to excess risk of thrombosis (factor V Leiden, lupus anticoagulant, factor C or S deficiency)

**Leg falls to bed by 5 seconds, but has some effort against gravity (taken from the NIH stroke scale)

‡Cancer (excluding non-melanoma skin cancer) present at any time in the last 5 years (cancer must be in remission to meet criteria)

*Immobilization is being confined to bed or chair with or without bathroom privileges

References:

1. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. *N Engl J Med*. 2020.
2. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. *N Engl J Med*. 2021;384(3):238-251.
3. Uno Y. Camostat mesilate therapy for COVID-19. *Intern Emerg Med*. 2020;15(8):1577-1578.
4. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. 2020;181(2):271-280 e278.
5. Kang YL, Chou YY, Rothlauf PW, et al. Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. *Proc Natl Acad Sci U S A*. 2020;117(34):20803-20813.
6. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *N Engl J Med*. 2020;Published online ahead of print.
7. Aranow C. Vitamin D and the immune system. *J Investig Med*. 2011;59(6):881-886.
8. Grant WB, Lahore H, McDonnell SL, et al. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. *Nutrients*. 2020;12(4).
9. Manion M, Hullsiek KH, Wilson EMP, et al. Vitamin D deficiency is associated with IL-6 levels and monocyte activation in HIV-infected persons. *PloS one*. 2017;12(5):e0175517.
10. Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. *Cellular & molecular immunology*. 2016;13(1):3-10.
11. Chen X, Zhao B, Qu Y, et al. Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019. *Clin Infect Dis*. 2020;71(8):1937-1942.
12. Annweiler C, Beaudenon M, Gautier J, et al. COvid-19 and high-dose VITamin D supplementation TRIAL in high-risk older patients (COVIT-TRIAL): study protocol for a randomized controlled trial. *Trials*. 2020;21(1):1031.
13. Bergman P, Lindh AU, Bjorkhem-Bergman L, Lindh JD. Vitamin D and Respiratory Tract Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *PloS one*. 2013;8(6):e65835.
14. Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. *BMJ*. 2017;356:i6583.
15. Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. *Am J Clin Nutr*. 2010;91(5):1255-1260.
16. Yakoob MY, Salam RA, Khan FR, Bhutta ZA. Vitamin D supplementation for preventing infections in children under five years of age. *Cochrane Database Syst Rev*. 2016;11:CD008824.
17. Charan J, Goyal JP, Saxena D, Yadav P. Vitamin D for prevention of respiratory tract infections: A systematic review and meta-analysis. *J Pharmacol Pharmacother*. 2012;3(4):300-303.
18. te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. *PLoS Pathog*. 2010;6(11):e1001176.
19. Carlucci PM, Ahuja T, Petrilli C, Rajagopalan H, Jones S, Rahimian J. Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients. *Journal of medical microbiology*. 2020;69(10):1228-1234.

20. Bhimraj A, Morgan R, Hirsch Shumaker A, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. <https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/>.
21. Hogan Ii RB, Hogan Iii RB, Cannon T, et al. Dual-histamine receptor blockade with cetirizine - famotidine reduces pulmonary symptoms in COVID-19 patients. *Pulm Pharmacol Ther.* 2020;63:101942.
22. Castiglione V, Chiriaco M, Emdin M, Taddei S, Vergaro G. Statin therapy in COVID-19 infection. *Eur Heart J Cardiovasc Pharmacother.* 2020;6(4):258-259.
23. DeDiego ML, Nieto-Torres JL, Regla-Nava JA, et al. Inhibition of NF-kappaB-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. *J Virol.* 2014;88(2):913-924.
24. Sheahan T, Morrison TE, Funkhouser W, et al. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. *PLoS Pathog.* 2008;4(12):e1000240.
25. Makris D, Manoulakas E, Komnos A, et al. Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study. *Crit Care Med.* 2011;39(11):2440-2446.
26. Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. *J Infect Dis.* 2012;205(1):13-19.
27. Brett SJ, Myles P, Lim WS, et al. Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. *PLoS one.* 2011;6(4):e18120.
28. Consortium WHOST, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med.* 2020.
29. Group RC, Horby P, Mafham M, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med.* 2020;383(21):2030-2040.
30. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents.* 2020:105949.
31. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res.* 2020;178:104787.
32. Alipio M. Vitamin D Supplementation Could Possibly Improve Clinical Outcomes of Patients Infected with Coronavirus-2019 (COVID-2019). . <https://ssrn.com/abstract=3571484>.
33. Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. *Aging Clin Exp Res.* 2020;32(7):1195-1198.
34. Tardif J-C, Bouabdallaoui N, INVESTIGATORS C. Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19. *medRxiv.* 2021.
35. Schlesinger N, Firestein BL, Brunetti L. Colchicine in COVID-19: an Old Drug, New Use. *Curr Pharmacol Rep.* 2020:1-9.
36. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. *Jama.* 2020;324(22):2292-2300.
37. Seftel D, Boulware D. Prospective cohort of fluvoxamine for early treatment of COVID-19. *Open Forum Infect Dis.* 2021:ofab050.
38. Medscape. Are Warnings Against NSAIDs in COVID-19 Warranted? <https://www.medscape.com/viewarticle/926940>.
39. FDA. FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19>.
40. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. *N Engl J Med.* 2020;382(25):2441-2448.
41. Mancía G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. *N Engl J Med.* 2020;382(25):2431-2440.
42. Zhang P, Zhu L, Cai J, et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. *Circ Res.* 2020;126(12):1671-1681.